Semaglutide Injection

Introduction Overview

Generic Name

semaglutide injection

Brand Name

Ozempic

Dosage Form

Single-patient-use injection pen (multiple strengths)

Drug Class

GLP-1 Agonists (Incretin Mimetics)

Pharmacokinetics

Absorption: Semaglutide administered via subcutaneous injection, as provided by Ozempic, has high bioavailability estimated at approximately 89% after a single dose. Its absorption is slow, with peak plasma levels occurring roughly 1 to 3 days post-injection, reflecting its long-acting profile suitable for once-weekly dosing. The absorption kinetics are consistent across injection sites (abdomen, thigh, upper arm). Food does not significantly affect absorption since the drug is injected subcutaneously.

Distribution: Semaglutide exhibits a large apparent volume of distribution compatible with extensive tissue distribution, including peripheral tissues. It is highly bound to plasma albumin (greater than 99%), resulting in a prolonged half-life by protecting it from degradation. The high plasma protein binding minimizes free drug levels but supports a sustained pharmacological effect.

Metabolism: Semaglutide is metabolized through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain but is not metabolized by cytochrome P450 enzymes. This non-CYP-dependent metabolism minimizes potential drug-drug interactions. The metabolic pathways result in smaller peptide fragments and amino acids, which are further metabolized or recycled in the body.

Elimination: Semaglutide has a long elimination half-life of approximately 7 days, allowing for once-weekly administration. The clearance is primarily via the kidneys and feces through catabolic pathways rather than glomerular filtration of the intact peptide. Less than 5% of semaglutide is excreted unchanged in urine. The elimination kinetics are prolonged due to extensive plasma protein binding and slow release from tissue compartments. Renal impairment may modestly affect clearance but no dosage adjustment is generally required in mild to moderate kidney disease.

Dosage Forms

Available Dosage Forms: Ozempic is supplied as a prefilled, single-patient-use injection pen designed for subcutaneous administration. There are three different strength pens available:
- 0.25 mg or 0.5 mg dose pen (contains 4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg)
- 1 mg dose pen (contains 4 doses of 1 mg)
- 2 mg dose pen (contains 4 doses of 2 mg)

Each pen carton includes NovoFine Plus needles suitable for subcutaneous use (6 needles with the 0.25/0.5 mg pen and 4 needles with the 1 mg and 2 mg pens). The injection pens are intended for use by one patient only and should never be shared.

Dosages for Adults and Adolescents: For adults with type 2 diabetes, the initial dosing regimen to minimize gastrointestinal side effects begins with 0.25 mg once weekly for the first 4 weeks. The dose is then increased to 0.5 mg once weekly for an additional 4 weeks. Patients requiring further glycemic control may titrate the dose to 1 mg once weekly after at least 4 weeks on 0.5 mg, and a maximum dose of 2 mg once weekly can be considered after at least 4 weeks on 1 mg. For reducing decline in kidney function and cardiovascular risks in type 2 diabetes patients with chronic kidney disease, the dosage follows a similar titration to a 1 mg maintenance dose.

Specific Patient Populations: Dose adjustment is generally not necessary for patients with mild to moderate renal impairment. It is not recommended for patients with severe gastroparesis or history of medullary thyroid carcinoma. No pediatric dosing for type 1 diabetes or children under 18 years is approved. Dosage adjustments may be necessary in patients who experience significant gastrointestinal side effects or hypoglycemia when combined with other antidiabetic drugs.

Mechanism Of Action

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the endogenous incretin hormone GLP-1. After food intake, GLP-1 is naturally secreted from the intestinal L-cells and regulates glucose homeostasis by enhancing glucose-dependent insulin secretion from pancreatic beta-cells while suppressing inappropriate glucagon release from alpha-cells. Semaglutide binds with high affinity to the GLP-1 receptor, activating adenylate cyclase and increasing intracellular cyclic AMP, which stimulates insulin secretion when glucose levels are elevated.

In addition to its insulinotropic effects, semaglutide delays gastric emptying by acting on the central nervous system and the gastrointestinal tract, leading to slower nutrient absorption and prolonged satiety. This mechanism contributes to reduced postprandial glucose excursions and decreased appetite, which support weight loss. The reduction in hepatic glucose output through lowered glucagon secretion also contributes significantly to improved glycemic control.

On a molecular level, semaglutide's structure includes a fatty acid side chain that facilitates sustained binding to albumin, prolonging its half-life and enabling once-weekly dosing. Clinical studies demonstrate that semaglutide reduces HbA1c levels effectively while improving beta-cell function and insulin sensitivity.

Beyond glycemic control, Ozempic has shown cardiovascular benefits by reducing major adverse cardiovascular events in patients with type 2 diabetes and existing cardiovascular disease. Its renal protective effects, observed in large clinical outcome trials, are postulated to result from improved glycemic control, reduced blood pressure, and direct renal effects possibly mediated via GLP-1 receptor activation in kidney tissues. The mechanisms underlying the reduction in kidney disease progression remain to be fully elucidated but are significant clinically.

Pharmacological Actions

Acts as a GLP-1 receptor agonist to enhance glucose-dependent insulin secretion.
Suppresses inappropriate glucagon secretion from pancreatic alpha cells.
Delays gastric emptying to reduce postprandial glucose excursions.
Decreases appetite and food intake contributing to weight loss.
Improves beta-cell function and insulin sensitivity in type 2 diabetes patients.
Exerts cardioprotective effects by reducing major cardiovascular adverse events.
Slows progression of chronic kidney disease in diabetic patients.
Maintains prolonged plasma concentrations due to albumin binding and resistance to enzymatic degradation.
Regulates hepatic glucose production by reducing glucagon levels.
Promotes satiety through central nervous system pathways.
Contributes to weight management as an adjunct to diet and exercise.
Reduces HbA1c and fasting plasma glucose effectively.
Demonstrates anti-inflammatory properties in some preclinical studies.
Has a favorable impact on cardiovascular mortality and morbidity in high-risk patients.
Improves postprandial glycemic control through multiple mechanisms.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus in adults to improve glycemic control.
Reduction of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease.
Reduction of risk for worsening kidney function, end-stage renal disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Adjunct therapy to diet and exercise for blood sugar (HbA1c) reduction.
Support for weight loss in patients with type 2 diabetes, contributing to improved metabolic outcomes.
Prolonged improvement in beta-cell function and insulin secretion.
Potential improvement in insulin sensitivity and metabolic parameters.
Off-label use consideration for weight management, though FDA-approved weight loss formulations differ (e.g., Wegovy).
Use in patients with moderate renal impairment without dosage adjustment.
Reduction of postprandial glucose spikes to minimize diabetes complications.
Alternative treatment option for patients inadequately controlled on other oral or injectable antidiabetic agents.
Adjunctive therapy reducing insulin or sulfonylurea doses when used in combination.
Demonstrated reduction in progression of diabetic kidney disease in clinical trials.
Useful in patients requiring cardiovascular risk reduction alongside diabetes treatment.
Widely accepted as a once-weekly injection improving patient adherence.

Side Or Adverse Effects

Nausea (15.8% to 20.3% incidence at 0.5 mg to 1 mg doses).
Vomiting (5% to 9.2%).
Diarrhea (8.5% to 8.8%).
Stomach pain or abdominal discomfort (5.7% to 7.3%).
Constipation (3.1% to 5%).
Loss of appetite potentially leading to weight loss.
Headache and dizziness reported in some patients.
Hypoglycemia, particularly when used with insulin or sulfonylureas (up to 29.8% symptomatic in insulin users).
Fatigue and tiredness during initiation phase.
Injection site reactions including redness or irritation.
Serious adverse events such as pancreatitis with symptoms of severe abdominal pain.
Possible thyroid tumors observed in rodent studies; unknown risk in humans.
Acute kidney injury related to volume depletion from gastrointestinal side effects.
Rare allergic reactions including hives, itching, or swelling.
Gastrointestinal symptoms tend to be transient and mild to moderate in severity during dose escalation.

Precautions

Do not use if allergic to semaglutide or any of its ingredients.
Avoid use if personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Use caution in patients with a history of pancreatitis.
Monitor patients for symptoms of acute kidney injury, especially with prolonged nausea, vomiting, or diarrhea.
Not recommended for patients with severe gastroparesis or substantial gastrointestinal motility disorders.
Ensure proper training on injection technique to avoid administration errors.
Pregnant women should discontinue at least 2 months prior to pregnancy; consult healthcare provider.
Unknown if excreted in breast milk; breastfeeding considerations warranted.
Monitor blood glucose closely when used with insulin or insulin secretagogues.
Educate patients about hypoglycemia signs and management.
Avoid sharing pens or needles to prevent infections.
Counsel on lifestyle measures to maximize therapeutic benefits.
Adjust dose gradually to minimize gastrointestinal side effects.
Ensure hydration during episodes of nausea or vomiting to prevent volume depletion.
Regular monitoring of thyroid function and screening for thyroid nodules may be considered.

Warnings

Potential risk of thyroid C-cell tumors based on rodent carcinogenicity studies, unknown in humans.
Not approved for treatment of type 1 diabetes or diabetic ketoacidosis.
Risk of pancreatitis has been reported; discontinue if pancreatitis is suspected.
Reports of stomach paralysis (ileus) post-marketing; monitor for symptoms like bloating and severe abdominal pain.
Monitor for signs of hypersensitivity reactions including anaphylaxis.
May increase risk of food or liquid aspiration during procedures requiring anesthesia or sedation.
Not recommended for patients with a history of medullary thyroid cancer or multiple endocrine neoplasia type 2 syndrome.
Risk of acute kidney injury due to dehydration from gastrointestinal adverse events.
Caution advised when used concomitantly with other glucose-lowering therapies to prevent hypoglycemia.
Use with caution in patients with diabetic retinopathy; monitor vision changes.
Patients should be informed about early symptoms of thyroid tumors.
If signs of allergic reactions occur, seek immediate medical attention.
Discontinue if severe gastrointestinal symptoms persist and hydration is compromised.
Avoid abrupt discontinuation to prevent glycemic instability.
Ensure proper patient education regarding proper handling and disposal of injectors.

Contraindication

Known hypersensitivity to semaglutide or any component in Ozempic.
Personal or family history of medullary thyroid carcinoma (MTC).
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
History of severe hypersensitivity reactions, including anaphylaxis or angioedema to GLP-1 receptor agonists.
Use in patients with type 1 diabetes or diabetic ketoacidosis is contraindicated.
Contraindicated if patient has severe gastrointestinal disease including gastroparesis.
Pregnancy due to lack of safety data and potential risk to fetus.
Known contraindication in patients with hypersensitivity to any injection pen components.
Patients with severe renal impairment or end-stage renal disease to be used cautiously based on clinical judgement.
Not approved for pediatric use (under 18 years old).
Contraindicated in patients with known hypersensitivity to other GLP-1 receptor agonists in some cases.
Use contraindicated if patient has active pancreatitis.
Individuals with acute illness involving severe gastrointestinal symptoms should defer use until resolved.
Avoid in patients receiving other experimental peptides or incretin analogues concurrently.
Contraindicated if unable to comply with injection technique or proper dosing schedule.

Drug Interactions

Concomitant use with insulin or sulfonylureas increases risk of hypoglycemia; dosage adjustment of such agents is recommended.
May slow gastric emptying, potentially delaying absorption of oral medications.
No significant interactions expected with cytochrome P450 metabolized drugs due to non-CYP metabolism.
Avoid sharing the injection pen to prevent cross-contamination and infections.
Caution when used with other GLP-1 receptor agonists (e.g., dulaglutide, liraglutide) to avoid additive effects.
Potential interaction with slow-acting oral medications; monitor clinical response.
Alcohol consumption may exacerbate hypoglycemia risks and gastrointestinal side effects.
Limited data on interactions with herbal supplements; caution advised.
Drugs affecting renal function should be monitored closely due to risk of volume depletion.
No formal interactions identified with common antihypertensive or lipid-lowering therapies.
May affect absorption of other orally administered drugs by delaying gastric emptying.
Careful monitoring advised when combined with other antidiabetic agents to balance glucose control and hypoglycemia risk.
No clinically relevant interactions observed with metformin in multiple clinical trials.
No interaction with warfarin or other anticoagulants reported, but monitoring is prudent.
Potential for interaction with other peptide-based drugs should be evaluated case-by-case.

Preparations Of The Drug

Ozempic injection pen is a prefilled, multi-dose device for subcutaneous administration.
Available in three strengths: 0.25 mg/0.5 mg pen, 1 mg pen, and 2 mg pen.
0.25/0.5 mg pen contains a mixture of doses with 4 doses at 0.25 mg and 2 or 4 doses at 0.5 mg depending on the presentation.
1 mg pen contains 4 doses of 1 mg each per pen.
2 mg pen contains 4 doses of 2 mg each per pen.
Each pen comes with NovoFine Plus needles for self-injection; needle sizes appropriate for subcutaneous injections.
Manufactured by Novo Nordisk, Denmark.
Inactive ingredients include disodium phosphate dihydrate, propylene glycol, phenol, and water for injection.
Stored refrigerated prior to first use; after first use, may be kept refrigerated or at room temperature for up to 56 days.
Pens should be disposed of 56 days after first use or when the dose counter indicates less than 0.25 mg remains.
Package includes detailed Instructions for Use for safe and effective administration.
Injection sites include abdomen, thigh, or upper arm for subcutaneous administration.
Pens intended for single patient use only, with needle replacement recommended for each injection.
Must not be shared to avoid risk of transmission of infectious diseases.
The pen design ensures accurate dosing via the dialed dose counter and auto-injector mechanism.
Packaging provides protection from light and contamination during storage.